Trial Profile

A phase Ib trial investigating huperzine-A in (BIS-001) in patients with refractory epilepsy

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Huperzine A (Primary)
Indications Complex partial epilepsy
Focus Adverse reactions; Proof of concept

Most Recent Events

24 Oct 2016 According to Biscayne Pharmaceuticals media release, company expects to advance this study in mid-2017.
28 Jun 2016 According to Biscayne Pharmaceuticals media release, company plans to initiate this study later this year.
28 Jun 2016 Planned initiation date changed from 1 Jan 2016 to 1 Nov 2016, as per Biscayne Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com